Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults

Clin Infect Dis. 2012 Jul;55(2):255-8. doi: 10.1093/cid/cis354. Epub 2012 Apr 11.

Author

John D Grabenstein¹

Affiliation

¹ Medical Affairs & Policy, Merck Vaccines, West Point, PA 19426, USA. [email protected]

PMID: 22495543
DOI: 10.1093/cid/cis354

No abstract available

MeSH terms

Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Pneumococcal Infections / epidemiology*
Pneumococcal Infections / microbiology*
Pneumococcal Infections / prevention & control
Pneumococcal Vaccines / administration & dosage
Pneumococcal Vaccines / immunology*
Serotyping
Streptococcus pneumoniae / classification*
Streptococcus pneumoniae / immunology*
Streptococcus pneumoniae / isolation & purification

Substances

13-valent pneumococcal vaccine
23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal Vaccines